SMShahriar Mobashery

Shahriar Mobashery

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shahriar Mobashery has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Dasantila Golemi

    Contribution from the Groupe de Cristallographie Biologique, Institut de Pharmacologie et de Biologie Structurale du CNRS, 205 route de Narbonne, 31077 Toulouse Cedex, France, and Institute for Drug Design and the Department of Chemistry, Wayne State University, Detroit, Michigan 48202-3489

    2 shared publications
  • Laurent Maveyraud

    Univ. Toulouse, CNRS, IPBS, Toulouse, France

    2 shared publications
  • Ioannis Grapsas

    Department of Chemistry, Institute for Drug Design, Wayne State University, Detroit, Michigan 48202, USA

    1 shared publication
  • Jalal Haddad

    <!--label omitted: 1-->Department of Chemistry, Wayne State University, Detroit, Michigan 48202

    1 shared publication
  • Jean-Pierre Samama

    Contribution from the Groupe de Cristallographie Biologique, Institut de Pharmacologie et de Biologie Structurale du CNRS, 205 route de Narbonne, 31077 Toulouse Cedex, France, and Institute for Drug Design and the Department of Chemistry, Wayne State University, Detroit, Michigan 48202-3489

    1 shared publication
  • Jean-Pierre Samama

    Groupe de Cristallographie Biologique, Institut de Pharmacologie et Biologie Structurale, 31077 Toulouse Cedex, France

    1 shared publication

Latest Publications

  • Molecular Dynamics at the Root of Expansion of Function in the M69L Inhibitor-Resistant TEM β-Lactamase from Escherichia coli

    by Samy O. Meroueh, Pierre Roblin, Dasantila Golemi, Laurent Maveyraud, Sergei B. Vakulenko, Yun Zhang, Jean-Pierre Samama, Shahriar Mobashery

    Clavulanate, an inhibitor for β-lactamases, was the very first inhibitor for an antibiotic resistance enzyme that found clinical utility in 1985. The clinical use of clavulanate and that of sulbactam and tazobactam, which were introduced to the clinic subsequently, has facilitated evolution of a set of β-lactamases that not only retain their original function as resistance enzymes but also are refractory to inhibition by the inhibitors. This article characterizes the properties of the clinically identified M69L mutant variant of the TEM-1 β-lactamase from Escherichia coli, an inhibitor-resistant β-lactamase, and compares it to the wild-type enzyme. The enzyme is as active as the wild-type in turnover of typical β-lactam antibiotics. Furthermore, many of the parameters for interactions of the inhibitors with the mutant enzyme are largely unaffected. The significant effect of the inhibitor-resistant trait was a relatively modest elevation of the dissociation constant for the formation of the pre-acylation complex. The high-resolution X-ray crystal structure for the M69L mutant variant revealed essentially no alteration of the three-dimensional structure, both for the protein backbone and for the positions of the side chains of the amino acids. It was surmised that the difference in the two enzymes must reside with the dynamic motions of the two proteins. Molecular dynamics simulations of the mutant and wild-type proteins were carried out for 2 ns each. Dynamic cross-correlated maps revealed the collective motions of the two proteins to be very similar, yet the two proteins did not behave identically. Differences in behavior of the two proteins existed in the regions between residues 145−179 and 155−162. Additional calculations revealed that kinetic effects measured experimentally for the dissociation constant for the pre-acylation complex could be mostly attributed to the electrostatic and van der Waals components of the binding free energy. The effects of the mutation on the behavior of the β-lactamase were subtle, including the differences in the measured dissociation constants that account for the inhibitor-resistant trait. It would appear that nature has selected for incorporation of the most benign alteration in the structure of the wild-type TEM-1 β-lactamase that is sufficient to give the inhibitor-resistant trait.


  • Critical involvement of a carbamylated lysine in catalytic function of class D β-lactamases

    by Dasantila Golemi, Laurent Maveyraud, Sergei Vakulenko, Jean-Pierre Samama, Shahriar Mobashery

    β-Lactamases are the resistance enzymes for β-lactam antibiotics, of which four classes are known. β-lactamases hydrolyze the β-lactam moieties of these antibiotics, rendering them inactive. It is shown herein that the class D OXA-10 β-lactamase depends critically on an unusual carbamylated lysine as the basic residue for both the enzyme acylation and deacylation steps of catalysis. The formation of carbamylated lysine is reversible. Evidence is presented that this enzyme is dimeric and carbamylated in living bacteria. High-resolution x-ray structures for the native enzyme were determined at pH values of 6.0, 6.5, 7.5, and 8.5. Two dimers are present per asymmetric unit. One monomer in each dimer was carbamylated at pH 6.0, whereas all four monomers were fully carbamylated at pH 8.5. At the intermediate pH values, one monomer of each dimer was carbamylated, and the other showed a mixture of carbamylated and non-carbamylated lysines. It would appear that, as the pH increased for the sample, additional lysines were “titrated” by carbamylation. A handful of carbamylated lysines are known from protein crystallographic data, all of which have been attributed roles in structural stabilization (mostly as metal ligands) of the proteins. This paper reports a previously unrecognized role for a noncoordinated carbamylate lysine as a basic residue involved in mechanistic reactions of an enzyme, which indicates another means for expansion of the catalytic capabilities of the amino acids in nature beyond the 20 common amino acids in development of biological catalysts.


  • Conjoint molecules of cephalosporins and aminoglycosides

    by Ioannis Grapsas, Stephen A. Lerner, Shahriar Mobashery


  • Open Access

    A 1.2-Å snapshot of the final step of bacterial cell wall biosynthesis

    by Wenlin Lee, Michael A. McDonough, Lakshmi P. Kotra, Zhi-Hong Li, Nicholas R. Silvaggi, Yoshifumi Takeda, Judith A. Kelly, Shahriar Mobashery

    The cell wall imparts structural strength and shape to bacteria. It is made up of polymeric glycan chains with peptide branches that are cross-linked to form the cell wall. The cross-linking reaction, catalyzed by transpeptidases, is the last step in cell wall biosynthesis. These enzymes are members of the family of penicillin-binding proteins, the targets of β-lactam antibiotics. We report herein the structure of a penicillin-binding protein complexed with a cephalosporin designed to probe the mechanism of the cross-linking reaction catalyzed by transpeptidases. The 1.2-Å resolution x-ray structure of this cephalosporin bound to the active site of the bifunctional serine type d -alanyl- d -alanine carboxypeptidase/transpeptidase (EC 3.4.16.4 ) from Streptomyces sp. strain R61 reveals how the two peptide strands from the polymeric substrates are sequestered in the active site of a transpeptidase. The structure of this complex provides a snapshot of the enzyme and the bound cell wall components poised for the final and critical cross-linking step of cell wall biosynthesis.


  • Top Cited Papers

    Aminoglycosides: Perspectives on Mechanisms of Action and Resistance and Strategies to Counter Resistance

    by Lakshmi P. Kotra, Jalal Haddad, Shahriar Mobashery

    Aminoglycosides are among the most commonly used broad-spectrum antibiotics in the anti-infective armamentar- ium. The vast majority of aminoglycosides are bactericidal, they have predictable pharmacokinetics, and they often act in syn- ergy with other antibiotics, properties that make them valuable as anti-infectives. Furthermore, despite the potential for renal toxicity, ototoxicity, and bacterial resistance, several members of this family of antibiotics have enjoyed clinical use for several decades.